Disclosures: Joseph Ahn: Nothing to Disclose, Nothing to Disclose, Hyunseok Kim: Nothing to Disclose, Michael Luu: Nothing to Disclose, Alexander Kuo: Nothing to Disclose, Walid Ayoub: Intercept: Speaking and Teaching, Mirum: Grant/Research Support, GSK: Consultant, GSK: Grant/Research Support, Madrigal: Grant/Research Support, Cymabay: Consultant, Ipsen: Grant/Research Support, Zydus: Grant/Research Support, Hirsh Trivedi: Nothing to Disclose, Yun Wang: Nothing to Disclose, Aarshi Vipani: Nothing to Disclose, Tsuyoshi Todo: Nothing to Disclose, Steven Wisel: Nothing to Disclose, Todd Brennan: Nothing to Disclose, Justin Steggerda: Nothing to Disclose, Joe Schwab: Nothing to Disclose, Irene Kim: Nothing to Disclose, Kambiz Kosari: Nothing to Disclose, Neehar Parikh: Genentech: Grant/Research Support, Exelixis: Grant/Research Support, Exelixis: Consultant, AstraZeneca: Consultant, Exact Sciences: Grant/Research Support, Exact Sciences: Consultant, Fujifilm Medical: Advisor, Amit Singal: Genentech: Consultant, AstraZeneca: Consultant, Bayer: Consultant, Eisai: Consultant, Exelixis: Consultant, Merck: Consultant, Elevar: Consultant, FujiFilm Medical Sciences: Consultant, Exact Sciences: Consultant, Glycotest: Consultant, Boston Scientific: Consultant, Sirtex: Consultant, HistoSonics: Consultant, Ju Dong Yang: Nothing to Disclose 1820 INTERACTION OF SOLUTE CARRIER FAMILY 39 MEMBER 1 AND DYNAMIN RELATED PROTEIN 1 TO FACILITATE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA BY IMPAIRING MITOCHONDRIAL QUALITY CONTROL Rui Li 1 Zhe Wang 1 Lixin Cheng 2 Zhiqiang Cheng 3 Qiong Wu 4 Qingxian Cai 5 Yijin Wang 1 , 1 SUSTech, 2 the First Affiliated Hospital of SUSTech, 3 The Second Affiliated Hospitalof SUSTech, 4 North Sichuan Medical College, 5 the Second Affiliated Hospital ofSUSTech Background: Despite rapid advances in HCC therapy, patients undergoing surgical resection have a poor prognosis with recurrence in the short-term
Additionally, their under-development triple agonist, Retatrutide, has shown unprecedented weight loss effects in phase 2 clinical trials
Overall, DPP4i have a favourable therapeutic profile and are safe and effective in the majority of patients with type 2 diabetes mellitus
Bovine colostrum is promoted for boosting immunity, preventing and treating diarrhea, and improving gut health, but does it really work
The large-scale STEP clinical trials (Semaglutide Treatment Effect in People with Obesity), published in the New England Journal of Medicine and JAMA, did not report increased cold sensitivity as a significant adverse effect
Energy deficiency may enhance intracortical remodeling and reduce periosteal bone apposition, leading to a net loss of cortical thickness and strength
